One‐Pot Synthesis of Oxygen Vacancy‐Rich Amorphous/Crystalline Heterophase CaWO<sub>4</sub> Nanoparticles for Enhanced Radiodynamic‐Immunotherapy
Radiodynamic therapy that employs X-rays to trigger localized reactive oxygen species (ROS) generation can tackle the tissue penetration issue of phototherapy. Although calcium tungstate (CaWO<sub>4</sub>) shows great potential as a radiodynamic agent benefiting from its strong X-ray absorption and the ability to generate electron-hole (e<sup>-</sup>-h<sup>+</sup>) pairs, slow charge carrier transfer and fast e<sup>-</sup>-h<sup>+</sup> recombination greatly limit its ROS-generating performance. Herein, via a one-pot wet-chemical method, oxygen vacancy-rich amorphous/crystalline heterophase CaWO<sub>4</sub> nanoparticles (Ov-a/c-CaWO<sub>4</sub> NPs) with enhanced radiodynamic effect are synthesized for radiodynamic-immunotherapy of cancer. The phase composition and oxygen vacancy content of CaWO<sub>4</sub> can be easily tuned by adjusting the solvothermal temperature. More intriguingly, the amorphous/crystalline interfaces and abundant oxygen vacancies accelerate charge carrier transfer and suppress e<sup>-</sup>-h<sup>+</sup> recombination, respectively, enabling synergistically improved ROS production from X-ray-irradiated Ov-a/c-CaWO<sub>4</sub> NPs. In addition to directly inducing oxidative damage of cancer cells, radiodynamic generation of ROS also boosts immunogenic cell death to provoke a systemic antitumor immune response, thereby allowing the inhibition of both primary and distant tumors as well as cancer metastasis. This study establishes a synergistic enhancement strategy involving the integration of phase and defect engineering to improve the ROS generation capacity of radiodynamic-immunotherapeutic anticancer nanoagents.
Authors
- Lisen Lin (ORCID: https://orcid.org/0000-0003-4060-8881)
- Shanshan Peng (ORCID: https://orcid.org/0000-0001-8630-1725)
- Huanghao Yang (ORCID: https://orcid.org/0000-0001-5894-0909)
- Tingting Cui (ORCID: https://orcid.org/0009-0006-2560-7812)
- Huilan Cai
- Xuegang Niu
- Hongwei Huang (ORCID: https://orcid.org/0000-0003-0271-1079)
- Rujiang Ao
- Jun Wang
- Xiaoyuan Shawn Chen (ORCID: https://orcid.org/0000-0002-9622-0870)
- Zhen Chen (ORCID: https://orcid.org/0000-0002-5843-0674)
- Meili Yu
Institutions
- Fujian Medical University (CN)
- National University of Singapore (SG)
- First Affiliated Hospital of Fujian Medical University (CN)
- Institute of Molecular and Cell Biology (SG)
- Fuzhou University (CN)
Publication Details
- Journal
- Advanced Science
- Published
- 2024-12-27
- DOI
- https://doi.org/10.1002/advs.202409551
- Citations
- 5
- Primary Topic
- Nanoplatforms for cancer theranostics
- Type
- article
- Field-Weighted Citation Impact
- 0.92
Funders
- National Natural Science Foundation of China
- National Key Research and Development Program of China